Circulation journal : official journal of the Japanese Circulation Society · 2010
Two-year clinical outcome after abciximab-coated stent implantation in patients with coronary artery disease.
Сравнительное исследованиеСтатьяРандомизированное исследованиеПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kim Sung Soo, Hong Young Joon, Jeong Myung Ho, Kim Weon, Kim Hyun-Kuk, Ko Jum Suk, Lee Min Goo, Sim Doo Sun, Park Keun Ho, Yoon Nam Sik, Yoon Hyun Ju, Kim Kye Hun, Park Hyung Wook, Kim Ju Han, Ahn Youngkeun, Cho Jeong Gwan, Park Jong Chun, Song Sun-Jung, Cho Dong Lyun, Kang Jung Chaee
Аннотация
BACKGROUND: Despite abciximab-coated stents having an inhibitory effect on coronary artery restenosis, the medium-term clinical outcome is unknown.
METHODS AND RESULTS: This prospective, randomized study compared the effects of the abciximab-coated stent, which was implanted in 95 patients, with those of control bare metal stents (BMS) implanted in 93 patients for de novo coronary lesions. Stent implantation was performed without any complications associated with the procedure. The 6-month intravascular ultrasound analysis showed that the area of neointimal hyperplasia was significantly smaller in the abciximab-coated stent group compared with the control stent group (+2.0+/-1.6 mm(2) vs +3.4+/-1.7 mm(2), P=0.001). However, at 2-year clinical follow up, there were no statistically significant differences in the incidences of total major adverse cardiac events (16% vs 24%, P=0.19) and cardiac death (0% vs 1.1%, P=0.3), target vessel revascularization (16% vs 21%, P=0.4) or non-fatal myocardial infarction (0% vs 2.3%, P=0.16) in the abciximab-coated stent group compared with the control stent group.
CONCLUSIONS: Although abciximab-coated stents are safe and inhibit neointimal hyperplasia, they have no superiority over BMS in 2-year clinical outcome.
METHODS AND RESULTS: This prospective, randomized study compared the effects of the abciximab-coated stent, which was implanted in 95 patients, with those of control bare metal stents (BMS) implanted in 93 patients for de novo coronary lesions. Stent implantation was performed without any complications associated with the procedure. The 6-month intravascular ultrasound analysis showed that the area of neointimal hyperplasia was significantly smaller in the abciximab-coated stent group compared with the control stent group (+2.0+/-1.6 mm(2) vs +3.4+/-1.7 mm(2), P=0.001). However, at 2-year clinical follow up, there were no statistically significant differences in the incidences of total major adverse cardiac events (16% vs 24%, P=0.19) and cardiac death (0% vs 1.1%, P=0.3), target vessel revascularization (16% vs 21%, P=0.4) or non-fatal myocardial infarction (0% vs 2.3%, P=0.16) in the abciximab-coated stent group compared with the control stent group.
CONCLUSIONS: Although abciximab-coated stents are safe and inhibit neointimal hyperplasia, they have no superiority over BMS in 2-year clinical outcome.
Предметные рубрики MeSH
AbciximabAgedAngioplasty, Balloon, CoronaryAntibodies, MonoclonalCoronary Artery DiseaseCoronary RestenosisCoronary ThrombosisDeath, Sudden, CardiacDisease-Free SurvivalDrug-Eluting StentsFemaleFollow-Up StudiesHumansImmunoglobulin Fab FragmentsIncidenceKaplan-Meier EstimateMaleMetalsMiddle AgedPlatelet Aggregation InhibitorsProspective StudiesTreatment OutcomeUltrasonography, Interventional